LOVFF (Cannara Biotech) Non Operating Income: $0.20 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOVFF Cannara Biotech Inc LOVFF
88 GF Score
Price $1.43
GF Value $1.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cannara Biotech Non Operating Income?

Cannara Biotech LOVFF 88 Non Operating Income is $0.20 Mil as of May. 2026. GuruFocus rates LOVFF with a GF Score™ of 88/100 and a GF Value™ of $1.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Cannara Biotech's Non Operating Income for the three months ended in May. 2026 was $-0.02 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 was $0.20 Mil.

Cannara Biotech Non Operating Income Related Terms

Cannara Biotech Non Operating Income Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Non Operating Income Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Non Operating Income
Get a 7-Day Free Trial -0.12 0.43 -0.05 1.40 0.31

Cannara Biotech Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.31 -0.04 -0.05 -0.02
LOVFF
88GF Score
Cannara Biotech Inc LOVFF
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.20 Mil mean?
Cannara Biotech (LOVFF) has a Non Operating Income of $0.20 Mil as of May. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Non Operating Income too high?
Cannara Biotech's current Non Operating Income is $0.20 Mil. Overall, Cannara Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Non Operating Income compare to ZTS?
Cannara Biotech's Non Operating Income of $0.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Non Operating Income is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.43 — trading 17.4% above its estimated fair value. The current Non Operating Income is $0.20 Mil. Cannara Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Non Operating Income is $0.20 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.43 is trading 17.4% above its estimated GF Value™ of $1.22. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • Non Operating Income: $0.20 Mil
  • GF Value™: $1.22 vs. price of $1.43 (17.4% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
88GF Score

Get the complete analysis for LOVFF

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.43
Price
$1.22
GF Value